Invivyd Completes Enrollment in Upsized Phase 3 COVID Antibody Trial, Results Expected Q3
IVVD has more than doubled off its 52-week low of $0.483.
Summary
Invivyd has completed enrollment for its Phase 3 DECLARATION clinical trial of VYD2311, an investigational COVID-19 antibody. The trial was previously upsized by approximately 500 subjects to increase statistical power, as announced in April. This milestone moves the company closer to top-line results, which are still expected in late Q3 2026. VYD2311 is a critical pipeline asset for Invivyd, especially following its recent Q1 net loss and 'going concern' warning.
At the time of this announcement, IVVD was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $335.9M. The 52-week trading range was $0.48 to $3.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.